June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Gene therapy rescues cone function and viability in Rp2 knockout mice over a broad vector dose range and a wide therapeutic time window
Author Affiliations & Notes
  • Suddhasil Mookherjee
    Ocular gene therapy unit, NIH, NEI, Bethesda, MD
  • Suja Hiriyanna
    Ocular gene therapy unit, NIH, NEI, Bethesda, MD
  • Kayleigh Kaneshiro
    Irvine School of Medicine, University of California, Irvin, CA
  • Haohua Qian
    NNRL, NIH, NEI, Bethesda, MD
  • Tiansen Li
    NNRL, NIH, NEI, Bethesda, MD
  • Hemant Khanna
    Department of Ophthalmology, University of Massachusetts Medical School, Worcester, MA
  • Peter Colosi
    Ocular gene therapy unit, NIH, NEI, Bethesda, MD
  • Anand Swaroop
    NNRL, NIH, NEI, Bethesda, MD
  • Zhijian Wu
    Ocular gene therapy unit, NIH, NEI, Bethesda, MD
  • Footnotes
    Commercial Relationships Suddhasil Mookherjee, None; Suja Hiriyanna, None; Kayleigh Kaneshiro, None; Haohua Qian, None; Tiansen Li, None; Hemant Khanna, None; Peter Colosi, None; Anand Swaroop, None; Zhijian Wu, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 2063. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Suddhasil Mookherjee, Suja Hiriyanna, Kayleigh Kaneshiro, Haohua Qian, Tiansen Li, Hemant Khanna, Peter Colosi, Anand Swaroop, Zhijian Wu; Gene therapy rescues cone function and viability in Rp2 knockout mice over a broad vector dose range and a wide therapeutic time window. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):2063.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Mutations in the RP2 gene account for ~10% of X-linked retinitis pigmentosa (XLRP). We recently generated an RP2 AAV vector (AAV8-scRK-RP2) and confirmed its ability to mediate long-term RP2 expression in Rp2 knockout (Rp2-KO) mouse model. Our initial results revealed cone function rescue in the mice receiving vector treatment at 4-6 weeks of age (ARVO 2014, poster 3310). The goal of this study was to conduct a long-term safety and efficacy investigation using a broad vector dose range. We also assessed whether older mice could benefit from the treatment.

Methods: Four to six-week old Rp2-KO mice received unilateral subretinal injections of the vector with doses of 5×107, 1×108, 3×108 or 1×109 vector genomes (vg) per eye. Fellow eyes were injected with vehicle. Another set of mice received 3×108 vg/eye injection at 10 months of age. Retinal function of the treated mice was assessed by electroretinography (ERG) and optomotor test. These mice were sacrificed at 6.5 or 18 months of age for immunofluorescence analyses.

Results: A consistently higher photopic ERG response was observed in the vector-treated eyes with a wide dose range (5×107 to 3×108 vg/eye) during the 18-month observation. These eyes also exhibited significantly higher visual acuity by optomotor test. M-opsin was mislocalized to inner segments, cell body and synaptic regions in vehicle injected retina but was primarily localized to outer segments in the vector-treated retina. In addition, higher expressions of Grk1 and cone-Pde were observed in the photoreceptor layer of vector treated eyes. The vector-treated eyes also maintained higher number of cone cells at 18 months of age. Interestingly, prevention of loss of cone function and viability was also achieved in Rp2-KO mice treated at 10 months of age. However, reduced rod ERG amplitude and thinner photoreceptor layer were observed in mice receiving the highest vector dose (1×109 vg/eye), indicating retinal toxicity caused by the over-expressed RP2 protein.

Conclusions: Administration of the AAV8-scRK-RP2 vector is able to prevent the loss of cone function and viability in Rp2-KO mice with a broad vector dose range. The wide therapeutic time window in mice suggests that patients with RP2 mutations could benefit even when treated at an advanced age. The AAV8-scRK-RP2 vector fits our criteria for further clinical development.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×